NCT06663436View on ClinicalTrials.gov

A Study on the Immune Response and Safety of a Multicomponent Shigella Vaccine in Preventing Shigellosis in Infants

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

November 13, 2024

Primary Completion Date

October 16, 2025

Study Completion Date

October 16, 2025

Conditions
Diarrhoea
Interventions
BIOLOGICAL

altSonflex1-2-3 Dose A

altSonflex1-2-3 Dose A administered intramuscularly on Day 1 and Day 169

BIOLOGICAL

altSonflex1-2-3 Dose B

altSonflex1-2-3 Dose B administered intramuscularly on Day 1 and Day 169

BIOLOGICAL

altSonflex1-2-3 Dose C

altSonflex1-2-3 Dose C administered intramuscularly on Day 1 and Day 169

BIOLOGICAL

TYPHIBEV

TYPHIBEV administered intramuscularly on Day 1

COMBINATION_PRODUCT

Infanrix hexa

Infanrix hexa administered intramuscularly on Day 169

BIOLOGICAL

MR-VAC

MR-VAC co-administered subcutaneously on Day 1 and Day 169

Trial Locations (1)

20200

GSK Investigational Site, Kericho

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT06663436 - A Study on the Immune Response and Safety of a Multicomponent Shigella Vaccine in Preventing Shigellosis in Infants | Biotech Hunter | Biotech Hunter